View More Recent Stories
-
AbbVie (ABBV) Acquires Celsius Therapeutics for $250 Million
-
AbbVie (ABBV) Introduces Alle Payment Plans
-
AbbVie (ABBV) Announces Second FDA Approval for EPKINLY
-
AbbVie (ABBV) Issues US Regulatory Update on ABBV-951
-
AbbVie (ABBV) Declares $1.55 Quarterly Dividend; 3.6% Yield
-
AbbVie (ABBV) Appoints Roxanne S. Austin to its Board
-
Abbvie (ABBV) PT Raised to $190 at Piper Sandler
-
AbbVie (ABBV) and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease
-
Top pharma stocks to own in 2024 – Citi
-
This pharma giant is 'firing on all cylinders' - Piper Sandler

